Home | GSK US
Ben Schwartz, VP of Oncology, shares his 20-year GSK journey, from drug discovery to leading research. Addressing Long-Standing Barriers to Adult Immunization Our COiMMUNITY Initiative fosters a systematic, collaborative, and approach to boost vaccinations.
Careers | GSK US
At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
Company | GSK US
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US
Press releases | GSK US
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma Regulatory designation based on promising early data in this rare bone cancer.
Products - GSK US
We deliver over 1.5 million doses of our vaccines every day; and 4 out of 10 infants born each year receive at least one GSK vaccine. Our vaccines portfolio targets infectious diseases at every stage of life, helping to protect people from RSV, meningitis, shingles, flu, polio and many more.
Contact us - GSK
Contact us online at GSK for You. RRC - a reimbursement support program that helps patients and healthcare professionals in the US with coverage, coding and reimbursement issues for certain GSK products.
Vaccines | GSK US
GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG. GSK websites; GSK Global website; Locations selector; Global Behind the science; GSKPro for HCPs; ViiV Healthcare; GSK study register; Business to Business; Quick links; Behind the science US edition;
Purpose, strategy and culture | GSK US
GSK is a company where outstanding people can thrive. We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in ...
PENMENVY, GSK’s 5-in-1 meningococcal vaccine, approved by US …
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years.
Locations | GSK US
Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG. GSK websites; GSK Global website; Locations selector; Global Behind the science; GSKPro for HCPs; ViiV Healthcare;